AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON November 25, 1997
REGISTRATION STATEMENT NO. 333-23037
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
POST-EFFECTIVE AMENDMENT NO. 1
TO FORM SB-2/A
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
---------------
SIGA PHARMACEUTICALS, INC.
(NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER)
DELAWARE 2834 13-3864870
(STATE OR OTHER (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER
JURISDICTION OF CLASSIFICATION CODE NUMBER) IDENTIFICATION NO.)
INCORPORATION OR
ORGANIZATION)
---------------
666 THIRD AVENUE
NEW YORK, NY 10017
(212) 681-4970
(ADDRESS AND TELEPHONE NUMBER OF PRINCIPAL
EXECUTIVE OFFICES AND PRINCIPAL PLACE OF BUSINESS)
---------------
DAVID H. DE WEESE, PRESIDENT AND CHIEF EXECUTIVE OFFICER
SIGA PHARMACEUTICALS, INC.
666 THIRD AVENUE
NEW YORK, NY 10017
(212) 681-4970
(NAME, ADDRESS AND TELEPHONE NUMBER OF AGENT FOR SERVICE)
---------------
COPIES TO:
ADAM EILENBERG, ESQ. KENNETH KOCH, ESQ.
EHRENREICH, EILENBERG, KRAUSE & ZIVIAN SQUADRON, ELLENOFF, PLESENT
11 EAST 44TH ST & SHEINFELD, LLP
NEW YORK, NY 10017 551 FIFTH AVENUE
(212) 986-9700 NEW YORK, NY 10176
FACSIMILE (212) 986-2399 (212) 476-8362
FACSIMILE (212) 697-6686
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as
practicable after this Registration Statement becomes effective. If any of the
securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, check
the following box: [ ]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of earlier effective
registration statement for the same offering. [_]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [_]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [_]
---------------
<PAGE>
SIGNATURES
IN ACCORDANCE WITH THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THE
UNDERSIGNED REGISTRANT CERTIFIES THAT IT HAS REASONABLE GROUNDS TO BELIEVE
THAT IT MEETS ALL OF THE REQUIREMENTS FOR FILING ON FORM SB-2 AND AUTHORIZED
THIS REGISTRATION STATEMENT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED,
THEREUNTO DULY AUTHORIZED, IN THE CITY OF NEW YORK, ON THE 14TH DAY OF
NOVEMBER, 1997.
SIGA Pharmaceuticals, Inc.
/s/ David H. de Weese
By: _________________________________
David H. de Weese
Chairman, President, Chief Executive
Officer and Director (Principal
Executive Officer)
IN ACCORDANCE WITH THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THIS
REGISTRATION STATEMENT OR AMENDMENT HAS BEEN SIGNED BELOW BY THE FOLLOWING
PERSONS IN THE CAPACITIES AND ON THE DATES INDICATED:
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
/s/ Joshua D. Schein Chief Financial Officer November 25, 1997
- ----------------------------------- (Principal Accounting and
Dr. Joshua D. Schein Financial Officer),
Executive Vice President,
Secretary and Director
/s/ Judson A. Cooper Executive Vice President and November 25, 1997
- ----------------------------------- Director
Judson A. Cooper
/s/ Terence E. Downer Director November 25, 1997
- -----------------------------------
Terence E. Downer
/s/ Donald S. Howard Director November 25, 1997
- -----------------------------------
Donald S. Howard
</TABLE>
II-1
<PAGE>
INDEX TO EXHIBITS
EXHIBIT
NUMBER PAGE
------- ----
10(o) Collaborative Research and License Agreement between the
Company and American Home Products Corporation, dated as of
July 1, 1997*
11(a) Statement re: Computation of per share earnings*
24(b) Consent of Price Waterhouse LLP*
27 Financial Data Scehdule
- ---------
* Previously filed.
II-2
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL
STATEMENT AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<S> <C> <C>
<PERIOD-TYPE> YEAR 6-MOS
<FISCAL-YEAR-END> DEC-31-1996 DEC-31-1997
<PERIOD-START> JAN-01-1996 JAN-01-1997
<PERIOD-END> DEC-31-1996 JUN-30-1997
<CASH> 42,190 129,913
<SECURITIES> 0 0
<RECEIVABLES> 0 0
<ALLOWANCES> 0 0
<INVENTORY> 0 0
<CURRENT-ASSETS> 528,676 541,109
<PP&E> 28,674 28,674
<DEPRECIATION> 7,249 12,028
<TOTAL-ASSETS> 580,918 558,364
<CURRENT-LIABILITIES> 180,938 1,309,582
<BONDS> 0 0
0 0
0 0
<COMMON> 337 337
<OTHER-SE> 399,643 (751,555)
<TOTAL-LIABILITY-AND-EQUITY> 580,918 558,364
<SALES> 0 0
<TOTAL-REVENUES> 0 0
<CGS> 0 0
<TOTAL-COSTS> 2,270,482 1,191,284
<OTHER-EXPENSES> 0 0
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> (2,306) 121,727
<INCOME-PRETAX> (2,268,176) (1,313,011)
<INCOME-TAX> 0 0
<INCOME-CONTINUING> (2,268,176) (1,313,011)
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> (2,268,176) (1,313,011)
<EPS-PRIMARY> (.66) (.36)
<EPS-DILUTED> (.66) (.36)
</TABLE>
